News

Obesity boosts postmenopausal breast cancer risk

View on the News

If not weight loss, what will reduce cancer risk?

This article makes an important contribution in extending and refining our understanding of one particular risk associated with overweight and obesity; namely the increase in postmenopausal, hormone receptor–positive breast cancer.

The researchers also made the frustrating observation that weight loss is not protective, which challenges the notion that patients who are overweight or obese should lose weight to reduce their cancer risk. The study highlights the need for clinical trials to explore whether weight loss or body composition changes in overweight and obesity can reduce breast cancer risk.

Dr. Clifford A. Hudis is from the Memorial Sloan Kettering Cancer Center in New York, and Dr. Andrew Dannenberg is from the Weill Cornell Medical College in New York. These comments are adapted from an editorial (JAMA Oncol. 2015 June 11 [doi: 10.1001/jamaoncol. 2015.1547]). The authors reported having no financial disclosures.


 

FROM JAMA ONCOLOGY

References

Women who are overweight and obese have a significantly higher risk of invasive breast cancer after menopause compared with normal-weight women, according to secondary analysis of data from the Women’s Health Initiative.

An analysis of data from 67,142 postmenopausal women aged 50-79 years found that women with a body mass index greater than 35 had a 58% increased risk of invasive breast cancer, compared with women with a BMI lower than 25. Obese women with a BMI of greater than 35 were also at increased risk for estrogen- and progesterone-receptor–positive breast cancer compared to normal-weight women (hazard ratio, 1.86), but they were not at increased risk for hormone receptor–negative breast cancer.

An analysis of postmenopausal women found that those with a body mass index greater than 35 had a 58% increased risk of invasive breast cancer, compared with women with a BMI lower than 25. Dr. Cecil Fox/National Cancer Institute

This group also had a twofold increase in the risk of being diagnosed with a larger tumor, and significantly higher risk of having positive lymph nodes, regional and/or distant stage, and also of dying after breast cancer, according to an article published June 11 in JAMA Oncology.

“Well-designed clinical trials are needed to definitively test whether weight loss and body composition changes in overweight and obese women or obesity prevention in women of normal weight will reduce breast cancer risk,” wrote Marian L. Neuhouser, Ph.D., of the Fred Hutchinson Cancer Research Center in Seattle, and her colleagues (JAMA Oncol. 2015. June 11 [doi: 10.1001/jamaoncol. 2015.1546]).

The Women’s Health Initiative programs are supported by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. One of the researchers disclosed having financial relationships with Novartis, Novo Nordisk, Pfizer, Genetech, and Amgen. The other researchers reported having no financial disclosures.

Recommended Reading

Biomarker predicts bone loss in premenopausal breast cancer patients
MDedge Endocrinology
VIDEO: SERMs move beyond osteoporosis, breast cancer prevention
MDedge Endocrinology
North America has highest rate of obesity-related cancers
MDedge Endocrinology
Breast cancer patients show poor adherence to cardiovascular, diabetes medications
MDedge Endocrinology
SEER: Breast cancer survivors at increased risk of thyroid cancer
MDedge Endocrinology
VIDEO: Following breast cancer diagnosis, risk of thyroid cancer rises
MDedge Endocrinology
Apple’s ResearchKit
MDedge Endocrinology
Class of 2015: New drugs projected to earn billions and billions
MDedge Endocrinology
ASCO: Precision medicine initiatives take wing
MDedge Endocrinology
ASCO: Adjuvant denosumab halves fracture risk for breast cancer patients on AIs
MDedge Endocrinology